普瑞巴林
止痛药
加巴喷丁
神经病理性疼痛
医学
药理学
电压依赖性钙通道
钙通道
麻醉
生物信息学
钙
内科学
生物
病理
替代医学
作者
Mark J. Field,Peter J. Cox,Emma Stott,Heather L. Melrose,James Offord,Ti‐Zhi Su,Steve Bramwell,Laura Corradini,Steven England,Joanna Shaw Winks,Ross A. Kinloch,Jan Hendrich,Annette Dolphin,Tony Webb,Dic Williams
标识
DOI:10.1073/pnas.0409066103
摘要
Neuropathic pain is a debilitating condition affecting millions of people around the world and is defined as pain that follows a lesion or dysfunction of the nervous system. This type of pain is difficult to treat, but the novel compounds pregabalin (Lyrica) and gabapentin (Neurontin) have proven clinical efficacy. Unlike traditional analgesics such as nonsteroidal antiinflammatory drugs or narcotics, these agents have no frank antiinflammatory actions and no effect on physiological pain. Although extensive preclinical studies have led to a number of suggestions, until recently their mechanism of action has not been clearly defined. Here, we describe studies on the analgesic effects of pregabalin in a mutant mouse containing a single-point mutation within the gene encoding a specific auxiliary subunit protein (alpha2-delta-1) of voltage-dependent calcium channels. The mice demonstrate normal pain phenotypes and typical responses to other analgesic drugs. We show that the mutation leads to a significant reduction in the binding affinity of pregabalin in the brain and spinal cord and the loss of its analgesic efficacy. These studies show conclusively that the analgesic actions of pregabalin are mediated through the alpha2-delta-1 subunit of voltage-gated calcium channels and establish this subunit as a therapeutic target for pain control.
科研通智能强力驱动
Strongly Powered by AbleSci AI